Amgen INC Form 4 insider transactions

Amgen Chairman and CEO Robert Bradway was granted over 91,000 equity units, including stock options and restricted stock, as part of his long-term compensation package.

Amgen's VP of Finance and CAO Matthew C. Busch was granted 455 restricted stock units and 2,969 stock options as part of a long-term incentive plan.

Amgen's EVP of Global Commercial Operations, Murdo Gordon, was granted over 27,000 equity units and options as part of the company's long-term incentive plan.

Amgen EVP and General Counsel Jonathan P. Graham received equity grants including 2,609 RSUs and 17,022 stock options.

Amgen EVP and CFO Peter H. Griffith was granted 3,640 restricted stock units and 23,752 non-qualified stock options.

Amgen SVP and CCO Nancy A. Grygiel disclosed the acquisition of restricted stock units and stock options as part of an equity incentive plan.

Amgen SVP of Business Development Rachna Khosla received a grant of 500 restricted stock units and 3,266 stock options.

Amgen SVP of Human Resources Derek Miller was granted 910 restricted stock units and 5,938 stock options as part of an equity incentive plan.

Amgen Inc. Executive Vice President and Chief Technology Officer David M. Reese was granted restricted stock units and stock options as part of the company's equity incentive plan.

Amgen EVP of Operations Esteban Santos received a grant of 2,730 restricted stock units and 17,814 stock options.

Amgen Director Omar Ishrak acquired 106.1925 shares of common stock through dividend equivalents.

Amgen Inc. Director Charles M. Holley acquired 128.9481 shares of common stock via dividend reinvestment.

Amgen Inc. Director Michael V. Drake acquired 79.6444 shares of common stock via dividend equivalents.

Amgen EVP of Operations Esteban Santos reported the disposition of 1,338 shares of common stock to cover tax obligations.

Amgen Inc. Executive Vice President and Chief Technology Officer David M. Reese reported the disposition of 1,433 shares of common stock to cover tax obligations.

Amgen Inc. SVP of Human Resources Derek Miller reported the disposition of 365 shares of common stock to cover tax obligations.

Amgen SVP of Business Development Rachna Khosla disposed of 225 shares to cover tax obligations related to equity vesting.

Amgen SVP and CCO Nancy A. Grygiel reported the sale of 1,237 shares and the withholding of 242 shares for tax obligations.

Amgen EVP and CFO Peter H. Griffith reported the disposition of 1,433 shares of common stock to cover tax obligations.

Amgen EVP and General Counsel Jonathan P. Graham reported the disposition of 1,257 shares of common stock to cover tax obligations.

Amgen Inc. Executive Vice President Murdo Gordon reported the disposition of 1,593 shares of common stock to satisfy tax withholding obligations.

Amgen Inc. VP of Finance and CAO Matthew C. Busch reported the disposition of 68 shares of common stock to cover tax obligations.

Amgen Chairman and CEO Robert A. Bradway reported the disposition of 5,057 shares of common stock to cover tax obligations related to equity vesting.

Amgen's EVP of Operations, Esteban Santos, reported a disposition of 5,621 common shares at $366.21 per share.

Amgen's EVP and Chief Technology Officer, David M. Reese, reported the disposition of 6,022 common shares for tax liability at $366.21 per share.

Amgen's SVP of Human Resources, Derek Miller, disposed of 1,616 shares of common stock at $366.21 per share to cover tax liabilities related to equity vesting.

Amgen's SVP of Business Development, Rachna Khosla, disposed of 707 shares of common stock to cover tax liabilities related to equity vesting.

Amgen's Senior Vice President and Chief Compliance Officer, Nancy A. Grygiel, reported the disposition of 787 shares of common stock at $366.21 per share.

Amgen's EVP & CFO, Peter H. Griffith, disposed of 5,748 shares of common stock to cover tax liabilities at a price of $366.21 per share.

Amgen's EVP & General Counsel, Jonathan P. Graham, disposed of 5,353 common shares to cover tax liabilities related to equity vesting.